Severe α1-antitrypsin deficiency associated with lower blood pressure and reduced risk of ischemic heart disease: a cohort study of 91,540 individuals and a meta-analysis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Severe α1-antitrypsin deficiency associated with lower blood pressure and reduced risk of ischemic heart disease : a cohort study of 91,540 individuals and a meta-analysis. / Winther, Sine Voss; Ahmed, Dunia; Al-Shuweli, Suzan; Landt, Eskild Morten; Nordestgaard, Børge Grønne; Seersholm, Niels; Dahl, Morten.

I: Respiratory research, Bind 23, Nr. 1, 55, 2022.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Winther, SV, Ahmed, D, Al-Shuweli, S, Landt, EM, Nordestgaard, BG, Seersholm, N & Dahl, M 2022, 'Severe α1-antitrypsin deficiency associated with lower blood pressure and reduced risk of ischemic heart disease: a cohort study of 91,540 individuals and a meta-analysis', Respiratory research, bind 23, nr. 1, 55. https://doi.org/10.1186/s12931-022-01973-3

APA

Winther, S. V., Ahmed, D., Al-Shuweli, S., Landt, E. M., Nordestgaard, B. G., Seersholm, N., & Dahl, M. (2022). Severe α1-antitrypsin deficiency associated with lower blood pressure and reduced risk of ischemic heart disease: a cohort study of 91,540 individuals and a meta-analysis. Respiratory research, 23(1), [55]. https://doi.org/10.1186/s12931-022-01973-3

Vancouver

Winther SV, Ahmed D, Al-Shuweli S, Landt EM, Nordestgaard BG, Seersholm N o.a. Severe α1-antitrypsin deficiency associated with lower blood pressure and reduced risk of ischemic heart disease: a cohort study of 91,540 individuals and a meta-analysis. Respiratory research. 2022;23(1). 55. https://doi.org/10.1186/s12931-022-01973-3

Author

Winther, Sine Voss ; Ahmed, Dunia ; Al-Shuweli, Suzan ; Landt, Eskild Morten ; Nordestgaard, Børge Grønne ; Seersholm, Niels ; Dahl, Morten. / Severe α1-antitrypsin deficiency associated with lower blood pressure and reduced risk of ischemic heart disease : a cohort study of 91,540 individuals and a meta-analysis. I: Respiratory research. 2022 ; Bind 23, Nr. 1.

Bibtex

@article{6837722638c347cc92bc6c378fa7fad1,
title = "Severe α1-antitrypsin deficiency associated with lower blood pressure and reduced risk of ischemic heart disease: a cohort study of 91,540 individuals and a meta-analysis",
abstract = "Background: Increased elastase activity in α1-antitrypsin deficiency may affect elasticity of the arterial walls, and thereby blood pressure and susceptibility to cardiovascular disease. We hypothesized that severe α1-antitrypsin deficiency is associated with reduced blood pressure and susceptibility to cardiovascular disease. Methods: We genotyped 91,353 adults randomly selected from the Danish general population and 187 patients from the Danish α1-Antitrypsin Deficiency Registry and recorded baseline blood pressure, baseline plasma lipids and cardiovascular events during follow-up. 185 participants carried the ZZ genotype, 207 carried the SZ genotype and 91,148 carried the MM genotype. Results: α1-Antitrypsin deficiency was associated with decreases in blood pressure of up to 5 mmHg for systolic blood pressure and up to 2 mmHg for diastolic blood pressure, in ZZ vs SZ vs MM individuals (trend test, P{\textquoteright}s ≤ 0.01). Plasma triglycerides and remnant cholesterol were reduced in ZZ individuals compared with MM individuals (t-test, P{\textquoteright}s < 0.001). α1-Antitrypsin deficiency was associated with lower risk of myocardial infarction (trend test P = 0.03), but not with ischemic heart disease, ischemic cerebrovascular disease or hypertension (trend test, P{\textquoteright}s ≥ 0.59). However, when results for ischemic heart disease were summarized in meta-analysis with results from four previous studies, individuals with versus without α1-antitrypsin deficiency had an odds ratio for ischemic heart disease of 0.66 (95% CI:0.53–0.84). Conclusions: Individuals with severe α1-antitrypsin deficiency have lower systolic and diastolic blood pressure, lower plasma triglycerides and remnant cholesterol, reduced risk of myocardial infarction, and a 34% reduced risk of ischemic heart disease.",
keywords = "Blood pressure, Cardiovascular disease, Epidemiology, Genetics, Lipids, SERPINA1, α-Antitrypsin deficiency",
author = "Winther, {Sine Voss} and Dunia Ahmed and Suzan Al-Shuweli and Landt, {Eskild Morten} and Nordestgaard, {B{\o}rge Gr{\o}nne} and Niels Seersholm and Morten Dahl",
note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
doi = "10.1186/s12931-022-01973-3",
language = "English",
volume = "23",
journal = "Respiratory Research (Print)",
issn = "1465-9921",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Severe α1-antitrypsin deficiency associated with lower blood pressure and reduced risk of ischemic heart disease

T2 - a cohort study of 91,540 individuals and a meta-analysis

AU - Winther, Sine Voss

AU - Ahmed, Dunia

AU - Al-Shuweli, Suzan

AU - Landt, Eskild Morten

AU - Nordestgaard, Børge Grønne

AU - Seersholm, Niels

AU - Dahl, Morten

N1 - Publisher Copyright: © 2022, The Author(s).

PY - 2022

Y1 - 2022

N2 - Background: Increased elastase activity in α1-antitrypsin deficiency may affect elasticity of the arterial walls, and thereby blood pressure and susceptibility to cardiovascular disease. We hypothesized that severe α1-antitrypsin deficiency is associated with reduced blood pressure and susceptibility to cardiovascular disease. Methods: We genotyped 91,353 adults randomly selected from the Danish general population and 187 patients from the Danish α1-Antitrypsin Deficiency Registry and recorded baseline blood pressure, baseline plasma lipids and cardiovascular events during follow-up. 185 participants carried the ZZ genotype, 207 carried the SZ genotype and 91,148 carried the MM genotype. Results: α1-Antitrypsin deficiency was associated with decreases in blood pressure of up to 5 mmHg for systolic blood pressure and up to 2 mmHg for diastolic blood pressure, in ZZ vs SZ vs MM individuals (trend test, P’s ≤ 0.01). Plasma triglycerides and remnant cholesterol were reduced in ZZ individuals compared with MM individuals (t-test, P’s < 0.001). α1-Antitrypsin deficiency was associated with lower risk of myocardial infarction (trend test P = 0.03), but not with ischemic heart disease, ischemic cerebrovascular disease or hypertension (trend test, P’s ≥ 0.59). However, when results for ischemic heart disease were summarized in meta-analysis with results from four previous studies, individuals with versus without α1-antitrypsin deficiency had an odds ratio for ischemic heart disease of 0.66 (95% CI:0.53–0.84). Conclusions: Individuals with severe α1-antitrypsin deficiency have lower systolic and diastolic blood pressure, lower plasma triglycerides and remnant cholesterol, reduced risk of myocardial infarction, and a 34% reduced risk of ischemic heart disease.

AB - Background: Increased elastase activity in α1-antitrypsin deficiency may affect elasticity of the arterial walls, and thereby blood pressure and susceptibility to cardiovascular disease. We hypothesized that severe α1-antitrypsin deficiency is associated with reduced blood pressure and susceptibility to cardiovascular disease. Methods: We genotyped 91,353 adults randomly selected from the Danish general population and 187 patients from the Danish α1-Antitrypsin Deficiency Registry and recorded baseline blood pressure, baseline plasma lipids and cardiovascular events during follow-up. 185 participants carried the ZZ genotype, 207 carried the SZ genotype and 91,148 carried the MM genotype. Results: α1-Antitrypsin deficiency was associated with decreases in blood pressure of up to 5 mmHg for systolic blood pressure and up to 2 mmHg for diastolic blood pressure, in ZZ vs SZ vs MM individuals (trend test, P’s ≤ 0.01). Plasma triglycerides and remnant cholesterol were reduced in ZZ individuals compared with MM individuals (t-test, P’s < 0.001). α1-Antitrypsin deficiency was associated with lower risk of myocardial infarction (trend test P = 0.03), but not with ischemic heart disease, ischemic cerebrovascular disease or hypertension (trend test, P’s ≥ 0.59). However, when results for ischemic heart disease were summarized in meta-analysis with results from four previous studies, individuals with versus without α1-antitrypsin deficiency had an odds ratio for ischemic heart disease of 0.66 (95% CI:0.53–0.84). Conclusions: Individuals with severe α1-antitrypsin deficiency have lower systolic and diastolic blood pressure, lower plasma triglycerides and remnant cholesterol, reduced risk of myocardial infarction, and a 34% reduced risk of ischemic heart disease.

KW - Blood pressure

KW - Cardiovascular disease

KW - Epidemiology

KW - Genetics

KW - Lipids

KW - SERPINA1

KW - α-Antitrypsin deficiency

U2 - 10.1186/s12931-022-01973-3

DO - 10.1186/s12931-022-01973-3

M3 - Journal article

C2 - 35264159

AN - SCOPUS:85126078127

VL - 23

JO - Respiratory Research (Print)

JF - Respiratory Research (Print)

SN - 1465-9921

IS - 1

M1 - 55

ER -

ID: 309125972